References

https://doi.org/10.1016/j.coemr.2020.10.005 Ahmed, M. B., Alghamdi, A. A., Islam, S. U., Lee, J.-S., & Lee, Y.-S. (2022). cAMP signaling in cancer: a PKA-CREB and EPAC-centric approach.Cells, 11 (13), 2020. Arora, C., Matic, M., Bisceglia, L., Di Chiaro, P., De Oliveira Rosa, N., Carli, F., … Raimondi, F. (2024). The landscape of cancer-rewired GPCR signaling axes. Cell Genomics, 4 (5)doi:10.1016/j.xgen.2024.100557Arora, K. K., Cheng, Z., & Catt, K. J. (1997). Mutations of the conserved DRS motif in the second intracellular loop of the gonadotropin-releasing hormone receptor affect expression, activation, and internalization. Molecular Endocrinology, 11 (9), 1203-1212. Baeissa, H., Benstead-Hume, G., Richardson, C. J., & Pearl, F. M. G. (2017). Identification and analysis of mutational hotspots in oncogenes and tumour suppressors.Oncotarget, 8 (13), 21290-21304. doi:10.18632/oncotarget.15514Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., … Reardon, B. (2018). Comprehensive characterization of cancer driver genes and mutations. Cell, 173 (2), 371-385. e318. Baldwin, J. M., Schertler, G. F., & Unger, V. M. (1997). An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. Journal of molecular biology, 272 (1), 144-164. Bányai, L., Trexler, M., Kerekes, K., Csuka, O., & Patthy, L. (2021). Use of signals of positive and negative selection to distinguish cancer genes and passenger genes. eLife, 10 , e59629. Bartfai, T., & Wang, M.-w. (2013). Positive allosteric modulators to peptide GPCRs: a promising class of drugs. Acta Pharmacologica Sinica, 34 (7), 880-885. Beck, A., & Reichert, J. M. (2012). Marketing approval of mogamulizumab: a triumph for glyco-engineering. In MAbs (Vol. 4, pp. 419-425): Taylor & Francis.Boland, J. W., & Pockley, A. G. (2018). Influence of opioids on immune function in patients with cancer pain: from bench to bedside. British journal of pharmacology, 175 (14), 2726-2736. Bongers, B., Gorostiola González, M., Wang, X., van Vlijmen, H., Jespers, W., Gutiérrez-de-Terán, H., … van Westen, G. (2022). Pan-cancer functional analysis of somatic mutations in G protein-coupled receptors. Scientific Reports, 12 (1), 21534. Bonomi, M., Proverbio, M. C., Weber, G., Chiumello, G., Beck-Peccoz, P., & Persani, L. (2001). Hyperplastic Pituitary Gland, High Serum Glycoprotein Hormoneα-Subunit, and Variable Circulating Thyrotropin (TSH) Levels as Hallmark of Central Hypothyroidism due to Mutations of the TSHβ Gene.The Journal of Clinical Endocrinology & Metabolism, 86 (4), 1600-1604. Bozic, I., Antal, T., Ohtsuki, H., Carter, H., Kim, D., Chen, S., … Nowak, M. A. (2010). Accumulation of driver and passenger mutations during tumor progression. Proceedings of the National Academy of Sciences, 107 (43), 18545-18550. Cai, B., El Daibani, A., Bai, Y., Che, T., & Krusemark, C. J. (2023). Direct Selection of DNA-Encoded Libraries for Biased Agonists of GPCRs on Live Cells.JACS Au, 3 (4), 1076-1088. doi:10.1021/jacsau.2c00674Cannavo, A., Liccardo, D., & Koch, W. J. (2013). Targeting cardiac β-adrenergic signaling via GRK2 inhibition for heart failure therapy. Frontiers in physiology, 4 , 264. Chaudhary, P. K., & Kim, S. (2021). An insight into GPCR and G-proteins as cancer drivers. Cells, 10 (12), 3288. Chen, T. Y., Chang, Y. C., Yu, C. Y., & Sung, W. W. (2024). Targeting the Adenosine A2A Receptor as a Novel Therapeutic Approach for Renal Cell Carcinoma: Mechanisms and Clinical Trial Review.Pharmaceutics, 16 (9)doi:10.3390/pharmaceutics16091127Chung, D. A., Wade, S. M., Fowler, C. B., Woods, D. D., Abada, P. B., Mosberg, H. I., & Neubig, R. R. (2002). Mutagenesis and peptide analysis of the DRY motif in the α2A adrenergic receptor: evidence for alternate mechanisms in G protein-coupled receptors. Biochemical and biophysical research communications, 293 (4), 1233-1241. den Hollander, L. S., Béquignon, O. J., Wang, X., van Wezel, K., Broekhuis, J., González, M. G., … Heitman, L. H. (2023). Impact of cancer-associated mutations in CC chemokine receptor 2 on receptor function and antagonism. Biochemical Pharmacology, 208 , 115399. Dixit, A., Yi, L., Gowthaman, R., Torkamani, A., Schork, N. J., & Verkhivker, G. M. (2009). Sequence and structure signatures of cancer mutation hotspots in protein kinases. PLoS One, 4 (10), e7485. Do, H. N., Haldane, A., Levy, R. M., & Miao, Y. (2022). Unique features of different classes of G‐protein‐coupled receptors revealed from sequence coevolutionary and structural analysis. Proteins: Structure, Function, and Bioinformatics, 90 (2), 601-614. Dorsam, R. T., & Gutkind, J. S. (2007). G-protein-coupled receptors and cancer. Nat Rev Cancer, 7 (2), 79-94. doi:10.1038/nrc2069Dorsam, R. T., & Gutkind, J. S. (2007). G-protein-coupled receptors and cancer. Nature reviews cancer, 7 (2), 79-94. Elia, J., Glessner, J. T., Wang, K., Takahashi, N., Shtir, C. J., Hadley, D., … Robison, R. (2012). Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder.Nature Genetics, 44 (1), 78-84. Faraoni, E. Y., Singh, K., Chandra, V., Le Roux, O., Dai, Y., Sahin, I., … Vucic, E. (2023). CD73-dependent adenosine signaling through Adora2b drives immunosuppression in ductal pancreatic cancer. Cancer Res, 83 (7), 1111-1127. Feng, W., & Song, Z. (2003). Effects of D3. 49A, R3. 50A, and A6. 34E mutations on ligand binding and activation of the cannabinoid-2 (CB2) receptor. Biochemical Pharmacology, 65 (7), 1077-1085. Flück, C. E., Martens, J. W., Conte, F. A., & Miller, W. L. (2002). Clinical, genetic, and functional characterization of adrenocorticotropin receptor mutations using a novel receptor assay.The Journal of Clinical Endocrinology & Metabolism, 87 (9), 4318-4323. Forbes, S. A., Beare, D., Boutselakis, H., Bamford, S., Bindal, N., Tate, J., … Ponting, L. (2017). COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Research, 45 (D1), D777-D783. Franco, R., Rivas-Santisteban, R., Navarro, G., & Reyes-Resina, I. (2021). Adenosine Receptor Antagonists to Combat Cancer and to Boost Anti-Cancer Chemotherapy and Immunotherapy. Cells, 10 (11)doi:10.3390/cells10112831Fredriksson, R., Lagerström, M. C., Lundin, L.-G., & Schiöth, H. B. (2003). The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Molecular pharmacology, 63 (6), 1256-1272. Fumarola, C., Bonelli, M. A., Petronini, P. G., & Alfieri, R. R. (2014). Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Biochemical Pharmacology, 90 (3), 197-207. Geraldo, L. H. M., Spohr, T. C. L. d. S., Amaral, R. F. d., Fonseca, A. C. C. d., Garcia, C., Mendes, F. d. A., … Lima, F. R. S. (2021). Role of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies. Signal transduction and targeted therapy, 6 (1), 45. Gondoh, E., Hamada, Y., Mori, T., Iwazawa, Y., Shinohara, A., Narita, M., … Tsujimura, M. (2022). Possible mechanism for improving the endogenous immune system through the blockade of peripheral μ-opioid receptors by treatment with naldemedine.British Journal of Cancer, 127 (8), 1565-1574. Grisshammer, R. (2017). New approaches towards the understanding of integral membrane proteins: A structural perspective on G protein‐coupled receptors.Protein Science, 26 (8), 1493-1504. Gurevich, V. V., & Gurevich, E. V. (2019). GPCR Signaling Regulation: The Role of GRKs and Arrestins.Front Pharmacol, 10 , 125. doi:10.3389/fphar.2019.00125Han, Y., Dong, C., Hu, M., Wang, X., & Wang, G. (2024). Unlocking the adenosine receptor mechanism of the tumour immune microenvironment. Front Immunol, 15 , 1434118. doi:10.3389/fimmu.2024.1434118Hao, Y., & Tatonetti, N. P. (2016). Predicting G protein-coupled receptor downstream signaling by tissue expression. Bioinformatics, 32 (22), 3435-3443. Harizi, H. (2013). The immunobiology of prostanoid receptor signaling in connecting innate and adaptive immunity.BioMed research international, 2013 (1), 683405. Haskó, G., Linden, J., Cronstein, B., & Pacher, P. (2008). Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nature reviews Drug discovery, 7 (9), 759-770. Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schiöth, H. B., & Gloriam, D. E. (2017). Trends in GPCR drug discovery: new agents, targets and indications. Nature reviews Drug discovery, 16 (12), 829-842. Hua Li, J., Jain, S., McMillin, S. M., Cui, Y., Gautam, D., Sakamoto, W., … Gavrilova, O. (2013). A novel experimental strategy to assess the metabolic effects of selective activation of a Gq-coupled receptor in hepatocytes in vivo.Endocrinology, 154 (10), 3539-3551. Huang, H., & Tao, Y.-X. (2014). Functions of the DRY motif and intracellular loop 2 of human melanocortin 3 receptor. J Mol Endocrinol, 53 (3), 319-330. Huh, E., Gallion, J., Agosto, M. A., Wright, S. J., Wensel, T. G., & Lichtarge, O. (2021). Recurrent high-impact mutations at cognate structural positions in class AG protein-coupled receptors expressed in tumors. Proceedings of the National Academy of Sciences, 118 (51), e2113373118. Insel, P., Snead, A., Murray, F., Zhang, L., Yokouchi, H., Katakia, T., … Wilderman, A. (2012). GPCR expression in tissues and cells: are the optimal receptors being used as drug targets?British journal of pharmacology, 165 (6), 1613-1616. Insel, P. A., Sriram, K., Gorr, M. W., Wiley, S. Z., Michkov, A., Salmerón, C., & Chinn, A. M. (2019). GPCRomics: an approach to discover GPCR drug targets. Trends in pharmacological sciences, 40 (6), 378-387. Insel, P. A., Sriram, K., Wiley, S. Z., Wilderman, A., Katakia, T., McCann, T., … Liu, D. (2018). GPCRomics: GPCR expression in cancer cells and tumors identifies new, potential biomarkers and therapeutic targets. Frontiers in Pharmacology, 9 , 431. JA, N. B., & Bishop, D. T. (2005). The genetics of susceptibility to cutaneous melanoma. Drugs of Today (Barcelona, Spain: 1998), 41 (3), 193-203. Jacquelot, N., Duong, C. P., Belz, G. T., & Zitvogel, L. (2018). Targeting chemokines and chemokine receptors in melanoma and other cancers. Frontiers in immunology, 9 , 2480. Kamps, A. R., & Coffman, C. R. (2005). G protein‐coupled receptor roles in cell migration and cell death decisions. Annals of the New York Academy of Sciences, 1049 (1), 17-23. Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., … Zheng, J. (2010). Diverse somatic mutation patterns and pathway alterations in human cancers. Nature, 466 (7308), 869-873. Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., … Wyczalkowski, M. A. (2013). Mutational landscape and significance across 12 major cancer types. Nature, 502 (7471), 333-339. Kapolka, N. J., Taghon, G. J., Rowe, J. B., Morgan, W. M., Enten, J. F., Lambert, N. A., & Isom, D. G. (2020). DCyFIR: a high-throughput CRISPR platform for multiplexed G protein-coupled receptor profiling and ligand discovery. Proc Natl Acad Sci U S A, 117 (23), 13117-13126. doi:10.1073/pnas.2000430117Kaye, S. B., Fehrenbacher, L., Holloway, R., Amit, A., Karlan, B., Slomovitz, B., … Chang, I. (2012). A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission.Clinical Cancer Research, 18 (23), 6509-6518. Kim, H. R., Duc, N. M., & Chung, K. Y. (2018). Comprehensive Analysis of Non-Synonymous Natural Variants of G Protein-Coupled Receptors. Biomol Ther (Seoul), 26 (2), 101-108. doi:10.4062/biomolther.2017.073Kohli, K., Pillarisetty, V. G., & Kim, T. S. (2022). Key chemokines direct migration of immune cells in solid tumors. Cancer gene therapy, 29 (1), 10-21. Korbecki, J., Kojder, K., Simińska, D., Bohatyrewicz, R., Gutowska, I., Chlubek, D., & Baranowska-Bosiacka, I. (2020). CC chemokines in a tumor: a review of pro-cancer and anti-cancer properties of the ligands of receptors CCR1, CCR2, CCR3, and CCR4.International journal of molecular sciences, 21 (21), 8412. Kroeze, W. K., Sassano, M. F., Huang, X.-P., Lansu, K., McCorvy, J. D., Giguère, P. M., … Roth, B. L. (2015). PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome.Nature Structural & Molecular Biology, 22 (5), 362-369. doi:10.1038/nsmb.3014Kruse, A. C., Hu, J., Pan, A. C., Arlow, D. H., Rosenbaum, D. M., Rosemond, E., … Dror, R. O. (2012). Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature, 482 (7386), 552-556. Kübler, E., & Albrecht, H. (2018). Large set data mining reveals overexpressed GPCRs in prostate and breast cancer: potential for active targeting with engineered anti-cancer nanomedicines. Oncotarget, 9 (38), 24882-24897. doi:10.18632/oncotarget.25427Kumar, S., Warrell, J., Li, S., McGillivray, P. D., Meyerson, W., Salichos, L., … Nielsen, M. M. (2020). Passenger mutations in more than 2,500 cancer genomes: overall molecular functional impact and consequences. Cell, 180 (5), 915-927. e916. Lacroix, A., Bourdeau, I., Chasseloup, F., Kamenický, P., Lopez, A. G., Louiset, E., & Lefebvre, H. (2024). Aberrant hormone receptors regulate a wide spectrum of endocrine tumors. Lancet Diabetes Endocrinol, 12 (11), 837-855. doi:10.1016/s2213-8587(24)00200-6Lappano, R., & Maggiolini, M. (2011). G protein-coupled receptors: novel targets for drug discovery in cancer.Nat Rev Drug Discov, 10 (1), 47-60. doi:10.1038/nrd3320Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., … Roberts, S. A. (2013). Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 499 (7457), 214-218. Lee, A., Rana, B., Schiffer, H., Schork, N., Brann, M., Insel, P., & Weiner, D. (2003). Distribution analysis of nonsynonymous polymorphisms within the G-protein-coupled receptor gene family. Genomics, 81 (3), 245-248. Lee, S. C., Dacheux, M. A., Norman, D. D., Balázs, L., Torres, R. M., Augelli-Szafran, C. E., & Tigyi, G. J. (2020). Regulation of tumor immunity by lysophosphatidic acid. Cancers, 12 (5), 1202. Lehmann-Che, J., Bally, C., Letouzé, E., Berthier, C., Yuan, H., Jollivet, F., … de Thé, H. (2018). Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia. Nat Commun, 9 (1), 2047. doi:10.1038/s41467-018-04384-5Lennon, F. E., Moss, J., Singleton, P. A., & Riou, B. (2012). The μ-opioid receptor in cancer progression: is there a direct effect? The Journal of the American Society of Anesthesiologists, 116 (4), 940-945. Leone, R. D., & Emens, L. A. (2018). Targeting adenosine for cancer immunotherapy. Journal for immunotherapy of cancer, 6 , 1-9. Linehan, D., Noel, M. S., Hezel, A. F., Wang-Gillam, A., Eskens, F., Sleijfer, S., … Diehl, J. (2018). Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts. In: American Society of Clinical Oncology.Liu, G., Duranteau, L., Carel, J.-C., Monroe, J., Doyle, D. A., & Shenker, A. (1999). Leydig-cell tumors caused by an activating mutation of the gene encoding the luteinizing hormone receptor.New England Journal of Medicine, 341 (23), 1731-1736. Liu, R., Chen, Y., Liu, G., Li, C., Song, Y., Cao, Z., … Liu, Y. (2020). PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell death & disease, 11 (9), 797. Lu, Z.-L., Curtis, C. A., Jones, P. G., Pavia, J., & Hulme, E. C. (1997). The role of the aspartate-arginine-tyrosine triad in the m1 muscarinic receptor: mutations of aspartate 122 and tyrosine 124 decrease receptor expression but do not abolish signaling. Molecular pharmacology, 51 (2), 234-241. Maceyka, M., Harikumar, K. B., Milstien, S., & Spiegel, S. (2012). Sphingosine-1-phosphate signaling and its role in disease.Trends in cell biology, 22 (1), 50-60. Matic, M., Miglionico, P., Tatsumi, M., Inoue, A., & Raimondi, F. (2023). GPCRome-wide analysis of G-protein-coupling diversity using a computational biology approach.Nature Communications, 14 (1), 4361. doi:10.1038/s41467-023-40045-yMcFarland, C. D., Yaglom, J. A., Wojtkowiak, J. W., Scott, J. G., Morse, D. L., Sherman, M. Y., & Mirny, L. A. (2017). The damaging effect of passenger mutations on cancer progression. Cancer Res, 77 (18), 4763-4772. Miyai, K. (2007). Congenital Thyrotropin Deficiency—From Discovery to Molecular Biology, Postgenome and Preventive Medicine—. Endocrine journal, 54 (2), 191-203. Nag, J. K., Rudina, T., Maoz, M., Grisaru-Granovsky, S., Uziely, B., & Bar-Shavit, R. (2018). Cancer driver G-protein coupled receptor (GPCR) induced β-catenin nuclear localization: the transcriptional junction. Cancer and Metastasis Reviews, 37 , 147-157. Nagahashi, M., Abe, M., Sakimura, K., Takabe, K., & Wakai, T. (2018). The role of sphingosine‐1‐phosphate in inflammation and cancer progression. Cancer science, 109 (12), 3671-3678. Nanba, K., Usui, T., Minamiguchi, S., Mori, Y., Watanabe, Y., Honda, K., … Yuno, A. (2012). Two rare TSH receptor amino acid substitutions in toxic thyroid adenomas. Endocrine journal, 59 (1), 13-19. New, D. C., & Wong, Y. H. (2007). Molecular mechanisms mediating the G protein-coupled receptor regulation of cell cycle progression. Journal of molecular signaling, 2 (1), 2. New, D. C., Wu, K., Kwok, A. W., & Wong, Y. H. (2007). G protein‐coupled receptor‐induced Akt activity in cellular proliferation and apoptosis. The FEBS journal, 274 (23), 6025-6036. Nickols, H. H., & Conn, P. J. (2014). Development of allosteric modulators of GPCRs for treatment of CNS disorders.Neurobiology of disease, 61 , 55-71. Nie, J. Z., Wang, M.-T., & Nie, D. (2023). Regulations of Tumor Microenvironment by prostaglandins.Cancers, 15 (12), 3090. O’hayre, M., Vázquez-Prado, J., Kufareva, I., Stawiski, E. W., Handel, T. M., Seshagiri, S., & Gutkind, J. S. (2013). The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nature reviews cancer, 13 (6), 412-424. O’Hayre, M., Degese, M. S., & Gutkind, J. S. (2014). Novel insights into G protein and G protein-coupled receptor signaling in cancer. Current opinion in cell biology, 27 , 126-135. Obinata, H., Gutkind, S., Stitham, J., Okuno, T., Yokomizo, T., Hwa, J., & Hla, T. (2014). Individual variation of human S1P1 coding sequence leads to heterogeneity in receptor function and drug interactions [S].Journal of lipid research, 55 (12), 2665-2675. Onken, M. D., Worley, L. A., Long, M. D., Duan, S., Council, M. L., Bowcock, A. M., & Harbour, J. W. (2008). Oncogenic mutations in GNAQ occur early in uveal melanoma. Investigative ophthalmology & visual science, 49 (12), 5230-5234. Ozga, A. J., Chow, M. T., & Luster, A. D. (2021). Chemokines and the immune response to cancer. Immunity, 54 (5), 859-874. Paek, J., Kalocsay, M., Staus, D. P., Wingler, L., Pascolutti, R., Paulo, J. A., … Kruse, A. C. (2017). Multidimensional Tracking of GPCR Signaling via Peroxidase-Catalyzed Proximity Labeling. Cell, 169 (2), 338-349.e311. doi:10.1016/j.cell.2017.03.028Perez Almeria, C. V., Setiawan, I. M., Siderius, M., & Smit, M. J. (2021). G protein-coupled receptors as promising targets in cancer. Current Opinion in Endocrine and Metabolic Research, 16 , 119-127. doi:Piaggio, F., Croce, M., Reggiani, F., Monti, P., Bernardi, C., Ambrosio, M., … Bordo, D. (2022). In uveal melanoma Gα-protein GNA11 mutations convey a shorter disease-specific survival and are more strongly associated with loss of BAP1 and chromosomal alterations than Gα-protein GNAQ mutations. European Journal of Cancer, 170 , 27-41. Pierce, K. L., Premont, R. T., & Lefkowitz, R. J. (2002). Seven-transmembrane receptors. Nature reviews Molecular cell biology, 3 (9), 639-650. Pon, J. R., & Marra, M. A. (2015). Driver and passenger mutations in cancer. Annual Review of Pathology: Mechanisms of Disease, 10 (1), 25-50. Qiu, G. H., Yu, B., & Ma, M. (2024). G protein-coupled receptor-mediated signaling of immunomodulation in tumor progression.Faseb j, 38 (14), e23829. doi:10.1096/fj.202400458RRaimondi, F., Inoue, A., Kadji, F. M., Shuai, N., Gonzalez, J.-C., Singh, G., … Aoki, J. (2019). Rare, functional, somatic variants in gene families linked to cancer genes: GPCR signaling as a paradigm. Oncogene, 38 (38), 6491-6506. Rasheed, S. A. K., Subramanyan, L. V., Lim, W. K., Udayappan, U. K., Wang, M., & Casey, P. J. (2022). The emerging roles of Gα12/13 proteins on the hallmarks of cancer in solid tumors.Oncogene, 41 (2), 147-158. doi:10.1038/s41388-021-02069-wRaza, S. I., Muhammad, D., Jan, A., Ali, R. H., Hassan, M., Ahmad, W., & Rashid, S. (2014). In silico analysis of missense mutations in LPAR6 reveals abnormal phospholipid signaling pathway leading to hypotrichosis.PLoS One, 9 (8), e104756. Rebecchi, M. J., & Pentyala, S. N. (2000). Structure, function, and control of phosphoinositide-specific phospholipase C. Physiological reviews, 80 (4), 1291-1335. Reifenberger, J., Wolter, M., Weber, R. G., Megahed, M., Ruzicka, T., Lichter, P., & Reifenberger, G. (1998). Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res, 58 (9), 1798-1803. Ricciotti, E., & FitzGerald, G. A. (2011). Prostaglandins and inflammation. Arteriosclerosis, thrombosis, and vascular biology, 31 (5), 986-1000. Römpler, H., Yu, H.-T., Arnold, A., Orth, A., & Schöneberg, T. (2006). Functional consequences of naturally occurring DRY motif variants in the mammalian chemoattractant receptor GPR33.Genomics, 87 (6), 724-732. Rovati, G. E., Capra, V., & Neubig, R. R. (2007). The highly conserved DRY motif of class AG protein-coupled receptors: beyond the ground state. Molecular pharmacology, 71 (4), 959-964. Salvadores, M., Mas-Ponte, D., & Supek, F. (2019). Passenger mutations accurately classify human tumors. PLoS computational biology, 15 (4), e1006953. Samama, P., Cotecchia, S., Costa, T., & Lefkowitz, R. (1993). A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model.Journal of Biological Chemistry, 268 (7), 4625-4636. Santarpia, L., Lippman, S. M., & El-Naggar, A. K. (2012). Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy. Expert opinion on therapeutic targets, 16 (1), 103-119. Semmlinger, A., von Schoenfeldt, V., Wolf, V., Meuter, A., Kolben, T. M., Kolben, T., … Wuerstlein, R. (2018). EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer. BMC cancer, 18 , 1-9. Shenoy, S. K., & Lefkowitz, R. J. (2005). Seven-transmembrane receptor signaling through β-arrestin. Science’s STKE . Shenoy, S. S., & Lui, F. (2023). Biochemistry, endogenous opioids. In StatPearls [Internet] : StatPearls Publishing.Shepard, D. R., & Dreicer, R. (2010). Zibotentan for the treatment of castrate-resistant prostate cancer. Expert Opinion on Investigational Drugs, 19 (7), 899-908. Sriram, K., Moyung, K., Corriden, R., Carter, H., & Insel, P. A. (2019). GPCRs show widespread differential mRNA expression and frequent mutation and copy number variation in solid tumors. PLOS Biology, 17 (11), e3000434. doi:10.1371/journal.pbio.3000434Stoy, H., & Gurevich, V. V. (2015). How genetic errors in GPCRs affect their function: possible therapeutic strategies. Genes & diseases, 2 (2), 108-132. Strazza, M., & Mor, A. (2020). The complexity of targeting chemokines to promote a tumor immune response.Inflammation, 43 (4), 1201-1208. Sun, C., Wang, B., & Hao, S. (2022). Adenosine-A2A receptor pathway in cancer immunotherapy.Frontiers in immunology, 13 , 837230. Sun, G. C., Ho, W. Y., Chen, B. R., Cheng, P. W., Cheng, W. H., Hsu, M. C., … Tseng, C. J. (2015). GPCR dimerization in brainstem nuclei contributes to the development of hypertension. British journal of pharmacology, 172 (10), 2507-2518. Tao, Y.-X. (2008). Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics. Pharmacology & therapeutics, 120 (2), 129-148. Thompson, G. L., Canals, M., & Poole, D. P. (2014). Biological redundancy of endogenous GPCR ligands in the gut and the potential for endogenous functional selectivity. Frontiers in Pharmacology, 5 , 262. Turan, S., & Bastepe, M. (2015). GNAS spectrum of disorders. Current osteoporosis reports, 13 , 146-158. Turan, S., Hughes, C., Atay, Z., Guran, T., Haliloglu, B., Clark, A. J., … Metherell, L. A. (2012). An atypical case of familial glucocorticoid deficiency without pigmentation caused by coexistent homozygous mutations in MC2R (T152K) and MC1R (R160W). The Journal of Clinical Endocrinology & Metabolism, 97 (5), E771-E774. Tyutyunnykova, A., Telegeev, G., & Dubrovska, A. (2017). The controversial role of phospholipase C epsilon (PLCε) in cancer development and progression. Journal of Cancer, 8 (5), 716. Usman, S., Khawer, M., Rafique, S., Naz, Z., & Saleem, K. (2020). The current status of anti-GPCR drugs against different cancers. Journal of Pharmaceutical Analysis, 10 (6), 517-521. Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz Jr, L. A., & Kinzler, K. W. (2013). Cancer genome landscapes. Science, 339 (6127), 1546-1558. Wang, C., Wu, H., Evron, T., Vardy, E., Han, G. W., Huang, X.-P., … Katritch, V. (2014). Structural basis for Smoothened receptor modulation and chemoresistance to anticancer drugs. Nature Communications, 5 (1), 4355. Wu, V., Yeerna, H., Nohata, N., Chiou, J., Harismendy, O., Raimondi, F., … Gutkind, J. S. (2019). Illuminating the Onco-GPCRome: Novel G protein–coupled receptor-driven oncocrine networks and targets for cancer immunotherapy. Journal of Biological Chemistry, 294 (29), 11062-11086. Young, D., Waitches, G., Birchmeier, C., Fasano, O., & Wigler, M. (1986). Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell, 45 (5), 711-719. Zhang, Y., & Wang, X. (2020). Targeting the Wnt/β-catenin signaling pathway in cancer. Journal of hematology & oncology, 13 (1), 165.